Salute e Benessere
Ziwig Endotest®: Scientific Validation Published in NEJM Evidence
The Ziwig Endotest® was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients' clinical status, ensuring full methodological independence and robustness.
The NEJM Evidence publication highlights exceptional diagnostic performance:
These results show that . Performance remained consistent across all subgroups, regardless of hormonal treatment, analgesic use, inclusion site, or sequencing conditions, confirming the reliability and reproducibility of the test in real-world settings.
Within the framework of the French national early access program for breakthrough technologies (Forfait Innovation), Ziwig Endotest® is now reimbursed and available on medical prescription in 100 hospitals across
France .
It is indicated for women aged 18 to 43 years with chronic pelvic pain suggestive of endometriosis, when imaging results are normal or inconclusive. The test can be prescribed outside any research study, providing women with rapid, non-invasive, and accurate access to diagnosis.
Endometriosis affects around 10% of women of reproductive age, with diagnostic delays often exceeding seven years. The validation and clinical deployment of Ziwig Endotest® mark a major step forward toward earlier, simpler, and more equitable diagnosis.
" said Yahya El Mir , Founder and President of Ziwig.
For more information: www.ziwig.com
Contact presse – Finn Partners
Marie-Hélène Coste & Aurélia Adloff
06 20 89 49 03 / 06 89 38 94 70
sante@finnpartners.com
Logo: https://mma.prnewswire.com/media/2835260/Ziwig_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ziwig-endotest-scientific-validation-published-in-nejm-evidence-302629366.html